Lab guide · Tissue & thymic peptides
What Is TB-500? Thymosin Beta-4 Peptide Research Overview
What is TB-500? It is a name used in the research market for thymosin beta-4, a 43-amino-acid actin-binding peptide, and sometimes for a short synthetic fragment of it. This guide separates the two, explains the actin biochemistry that is well established, and shows how far the tissue-repair findings extend.
Key takeaways
- The name TB-500 is used for full-length thymosin beta-4 (43 residues, about 4963.5 g/mol) and also for a short synthetic fragment, so the molecule must always be stated.
- Thymosin beta-4 binds monomeric G-actin in a 1:1 complex and is a major actin-sequestering protein in mammalian cells.
- Cardiac, wound-healing and corneal findings come from cell and animal models of the full-length protein, not from the fragment.
- Thymosin beta-4 and its derivatives, for example TB-500, are named on the WADA Prohibited List, and neither form is an approved medicine.
What is TB-500?
So, what is TB-500? The label is ambiguous. Baltic Peptides supplies it as synthetic thymosin beta-4 (Tβ4), the full 43-residue, N-acetylated peptide, and that is the molecule this article describes. Elsewhere, “TB-500” is also used for a short N-acetylated fragment, commonly given as Ac-LKKTETQ and corresponding to residues 17–23 of Tβ4. A sequence overlap does not make the fragment equivalent to the whole protein, so findings must be assigned to the right molecule.
Tβ4 was described as the major actin-sequestering molecule in eukaryotic cells, with later work on dermal and corneal wound healing (Goldstein et al., 2005).
Research use only. This overview summarises published laboratory and animal research. Baltic Peptides supplies this compound for in-vitro and preclinical research by qualified researchers; it is not a medicine and is not for human or veterinary use.
Chemical structure and specifications
| Property | Full-length thymosin beta-4 |
|---|---|
| Sequence | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES |
| Length | 43 residues, N-terminally acetylated |
| Molecular formula | C212H350N56O78S |
| Molecular weight | ≈4963.5 g/mol (average) |
| CAS number | 77591-33-4 |
| Actin-binding motif | LKKTET (residues 17–22) |
| Oxidation-prone residue | One methionine (position 6) |
The formula matches the PubChem record, and the average mass calculated from that formula is 4963.5 g/mol. The CAS number and sequence are those listed on the Baltic Peptides TB-500 product page. A seven-residue fragment would weigh under 1,000 Da, so intact-mass testing separates the two forms immediately.
Discovery and research history
Thymosins take their name from the thymus, where the family was first isolated. Goldstein and Kleinman (2015) review the discovery and isolation of Tβ4 and the tissue-repair studies that followed, which led to planned and ongoing trials in eye injury, dermal wounds, cardiac repair and neurological injury.
Interest in cardiac repair grew after reports that Tβ4 promotes cardiomyocyte and endothelial migration and survival (a 2007 report), and later work on epicardial progenitor cells summarised by Bollini et al. (2015).
Mechanism: actin sequestration and signalling
Actin binding
The best-established property of Tβ4 is binding to monomeric G-actin in a 1:1 complex, which prevents polymerisation into filaments and holds a reserve pool that cells draw on to move. The central LKKTET motif is the core actin-contact region.
Signalling findings
In cardiomyocyte cultures and mice, Tβ4 formed a functional complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt, and Akt activity was needed for its effects (a 2007 report). A later review links its many effects to indirect regulation of cell motility through the SRF–MRTF–G-actin transcriptional pathway (2016 review).
Main research areas
- Actin dynamics and cell migration: lamellipodia formation and motility in endothelial cells, keratinocytes and fibroblasts.
- Wound and corneal models: dermal and corneal healing in rodents.
- Cardiac injury: cardiomyocyte survival and epicardial progenitor activation after coronary ligation in mice.
- Angiogenesis: endothelial tube formation and vessel growth in animal models.
What published studies actually show
Reviews report that Tβ4 treatment reduced infarct volume and preserved function in preclinical models of cardiac ischaemic injury (Cardioprotection review). The table separates the evidence types.
| Evidence type | What is reported |
|---|---|
| Chemical facts | Sequence, formula and mass of Tβ4 are database-verifiable. |
| Biochemistry | 1:1 G-actin sequestration, central to its function. |
| Cell studies | Migration and survival of cardiac and endothelial cells; ILK–Akt signalling. |
| Animal studies | Cardiac, dermal and corneal repair endpoints in mice and rodents; full-length Tβ4 only. |
| Human research | Clinical trials of Tβ4 have been run or proposed; none has led to approval, and trial results do not transfer to the fragment. |
Scientific limitations and open questions
- The name is applied to two different molecules, which makes literature searches and product comparisons unreliable.
- Most mechanistic and repair findings concern the full-length protein, not the fragment.
- Many effects are pleiotropic and the signalling is indirect, which makes a single mechanism hard to isolate.
- Animal benefits have not been confirmed by an approved human indication.
- Thymosin beta-4 and its derivatives, for example TB-500, are listed in section S2 of the WADA Prohibited List.
Analytical and laboratory considerations
At nearly 5 kDa, Tβ4 needs intact-mass analysis to confirm identity and to separate it from a fragment. The methionine at position 6 can oxidise to the sulfoxide, which adds about 16 Da and is visible by mass spectrometry. That residue makes light, air and heat exposure relevant to storage.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the TB-500 product page.
Sources and further reading
- Goldstein A.L. and Kleinman H.K. (2015). Advances in the basic and clinical applications of thymosin β4. Expert Opin Biol Ther. PubMed
- Goldstein A.L. et al. (2005). Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. PubMed
- Thymosin β4 is cardioprotective after myocardial infarction (2007). PubMed
- Cardioprotection by Thymosin Beta 4 (2016 review). PubMed
- WADA Prohibited List, section S2. WADA · PubChem: Thymosin Beta 4
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article summarises published research for educational purposes only and does not describe any use in people.
FAQ
Common questions
What is TB-500?
Is TB-500 the same as thymosin beta-4?
What is the sequence of thymosin beta-4?
What is the molecular weight and CAS number of TB-500?
How does thymosin beta-4 bind actin?
Is there human evidence for TB-500?
Is TB-500 banned in sport?
Keep reading
Related reading
TB-500
Current batches, formats and the COA for TB-500.
What is BPC-157?
A gastric-derived peptide with a different studied pathway profile.
Peptide blends explained
Why component research does not define a combined formulation.
Research-grade TB-500, tested before it ships
Independent HPLC and mass spec results for every batch, dispatched from the EU.
